Trial Profile
A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Proof of concept; Therapeutic Use
- 08 Jun 2023 Planned number of patients changed from 28 to 36.
- 08 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 28 Apr 2023 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.